|
|
Blood, 1 June 2008, Vol. 111, No. 11, pp. 5359-5370.
Prepublished online as a Blood First Edition Paper on February 27, 2008; DOI 10.1182/blood-2007-08-105395.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma
Sajjan Mittal1,
Neil A. Marshall2,
Linda Duncan2,
Dominic J. Culligan1,
Robert N. Barker2, and
Mark A. Vickers2
1 Department of Clinical Haematology, Aberdeen Royal Infirmary, Aberdeen; and
2 Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom
Regulatory T (Treg) cells contribute to immune evasion by malignancies. To investigate their importance in non-Hodgkin lymphoma (NHL), we enumerated Treg cells in peripheral blood mononuclear cells (PBMCs) and involved tissues from 30 patients. CD25+FoxP3+CD127lowCD4+ Treg cells were increased markedly in PBMCs (median = 20.4% CD4 T cells, n = 20) versus healthy controls (median = 3.2%, n = 13, P < .001) regardless of lymphoma subtype, and correlated with disease stage and serum lactate dehydrogenase (Rs = 0.79, P < .001). T-cell hyporesponsiveness was reversed by depleting CD25+ cells, or by adding anti–CTLA-4, supporting the view that Treg cells explain the systemic immunosuppression seen in NHL. A high proportion of Treg cells was also present in involved tissues (median = 38.8% CD4 T cells, n = 15) versus reactive nodes (median = 11.6%, n = 2, P = .02). When autologous CD25– PBMC fractions were incubated with tumor cells from patients (n = 6) in vitro, there was consistent strong induction and then expansion of cells with the CD4+CD25+FoxP3+ phenotype of classic "natural" Treg cells. This population was confirmed to be suppressive in function. Direct cell-cell interaction of tumor cells with CD25– PBMCs was important in Treg induction, although there was heterogeneity in the mechanisms responsible. We conclude that NHL cells are powerful inducers of Treg cells, which may represent a new therapeutic target.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Vickers
The doctor's dilemma: stimulating T cells
Blood,
October 15, 2009;
114(16):
3361 - 3362.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Burger, P. Ghia, A. Rosenwald, and F. Caligaris-Cappio
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Blood,
October 15, 2009;
114(16):
3367 - 3375.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Y. Kim, Y. K. Jeon, T. M. Kim, J. E. Kim, Y. A. Kim, S.-H. Lee, D.-W. Kim, D. S. Heo, and C.-W. Kim
Increased quantity of tumor-infiltrating FOXP3-positive regulatory T cells is an independent predictor for improved clinical outcome in extranodal NK/T-cell lymphoma
Ann. Onc.,
October 1, 2009;
20(10):
1688 - 1696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. K. Nevala, C. M. Vachon, A. A. Leontovich, C. G. Scott, M. A. Thompson, S. N. Markovic, and for the Melanoma Study Group of the Mayo Clinic Ca
Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma
Clin. Cancer Res.,
March 15, 2009;
15(6):
1931 - 1939.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Blood,
March 12, 2009;
113(11):
2394 - 2401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Di Nicola, R. Zappasodi, C. Carlo-Stella, R. Mortarini, S. M. Pupa, M. Magni, L. Devizzi, P. Matteucci, P. Baldassari, F. Ravagnani, et al.
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
Blood,
January 1, 2009;
113(1):
18 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
